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Transforming growth factor-beta (TGF-β) has been demonstrated as a key regulator of immune responses including monocyte/
macrophage functions. TGF-β regulates macrophage cell migration and polarization, as well as it is shown to modulate
macrophage urokinase-type plasminogen activator (uPA) production, which also contributes to macrophage chemotaxis and
migration toward damaged or inflamed tissues. Microtubule (MT) cytoskeleton dynamic plays a key role during the cell
motility, and any interference on the MT network profoundly affects cell migration. In this study, by using estramustine
phosphate (EP), which modifies MT stability, we analysed whether tubulin cytoskeleton contributes to TGF-β-induced
macrophage cell migration and uPA expression. We found out that, in the murine macrophage cell line RAW 264.7, EP at
noncytotoxic concentrations inhibited cell migration and uPA expression induced by TGF-β. Moreover, EP greatly reduced the
capacity of TGF-β to trigger the phosphorylation and activation of its downstream Smad3 effector. Furthermore, Smad3
activation seems to be critical for the increased cell motility. Thus, our data suggest that EP, by interfering with MT dynamics,
inhibits TGF-β-induced RAW 264.7 cell migration paralleled with reduction of uPA induction, in part by disabling Smad3
activation by TGF-β.
1. Introduction
Transforming growth factor-β (TGF-β) plays multifunc-
tional roles in the homeostasis of the immune system by
acting as one of the most potent immunosuppressive factors
during inflammation progression and resolution [1, 2]. For
instance, TGF-β regulates both the adaptive and innate
immune cell recruitment to the site of inflammation [3].
Actually, this cytokine has profound effects on innate
immune cells including myeloid precursors, mast cells,
myeloid-derived suppressor cells, dendritic cells, neutrophils,
and monocytes/macrophages [4]. Namely, macrophages
express a continuum phenotype from classical activated
macrophages or M1, with proinflammatory and antitumor
properties to alternative activated macrophages or M2, which
possesses immunosuppressive, anti-inflammatory and protu-
moral characteristics [5]. TGF-β induces macrophage polari-
zation toward M2 phenotype, which helps in the process
of adaptive immune system suppression and tissue repair
[6, 7]. Moreover, in tumor microenvironment, TGF-β pro-
vokes macrophage differentiation toward a tumor-associated
macrophages- (TAM-) like (M2-like) phenotype [8]. Both
M2 and/or TAM cells are major sources of proteolytic
enzymes that contribute to extracellular matrix (ECM)
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reorganization and favour the invasion of neoplastic cells [9].
One of the most expressed macrophage-activated ECM-
degrading proteases is urokinase-type plasminogen activator
(uPA) [7]. uPA critically regulates monocyte/macrophage
chemotaxis and migration, and it contributes to differentia-
tion of monocytes into macrophages, participates in the
induction ofM2phenotype, and seems to be essential formac-
rophage infiltration into tumor microenvironment [10–15].
Macrophages are highly motile cells that quickly migrate
in the direction of a specific signal, and this is accompanied
by changes in the cell body and dynamic cytoskeletal rear-
rangement [16]. Namely, themicrotubules (MT) cytoskeleton
network plays several key roles in macrophage cell function,
including antigen presentation, phagocytosis, and migration
[17, 18]. The interference in microtubule organizing centre
and MT network highly affects macrophage motility and
directional migration patterns [19]; as a consequence, MT
cytoskeleton is a potential target in tumor chemotherapies.
Estramustine phosphate (EP), a nitrogen mustard deriv-
ative of estradiol-17β-phosphate, is an antineoplastic agent
that suppresses the MT dynamics, functions as antimitotic
agent, and may trigger cell death by disrupting the nuclear
matrix. Specifically, EP in vitro weakly inhibits polymeriza-
tion and induces depolymerization by interacting with
microtubule-associated protein or by direct interaction with
tubulin [20, 21]. Initially, EP was thought as a double alkylat-
ing and estrogenic agent, but although it reduces plasma
testosterone levels, by suppression of the pituitary–gonadal
axis as results of estrone and estradiol produced by hydrolysis
of EP, the putative alkylating effects are disabled [22].
TGF-β mainly transduces intracellular signaling via
phosphorylation and activation of Smad2/3 transcription
factors. These Smads interact with Smad4, and then this
complex is translocated to the nucleus to exert its function
on gene expression [23]. Intriguingly, it has been described
that Smads binding to MT may regulate TGF-β signaling
[24], which suggests that MT may play a regulatory role in
TGF-β intracellular signal activity.
We previously demonstrated that TGF-β induces uPA
expression via activation of Smad3 signaling in murine mac-
rophages [25], so regarding the importance of uPA and MT
network on cell migration, here, we determine whether the
chemotherapeutic approach targeting microtubule dynamic
by EP can modify the macrophage cell responses to TGF-β.
We found out that EP, at non-antiproliferative concentra-
tions, strongly reduces the cell migration induced by TGF-β,
probably by inhibiting Smad3 activation and subsequent
blocking of TGF-β-induced uPA in murine macrophages.
2. Material and Methods
2.1. Cell Line and Culture Conditions. Mouse macrophage
RAW 264.7 (ATCC TIB-71) cell line was kindly provided
by Dr. Carmelo Bernabeu (CIB, CSIC, Madrid, Spain). Cells
were cultured in RPMI containing 10% FBS supplemented
with antibiotics (100 units/ml streptomycin and 100 units/ml
penicillin) in a 5% CO2 at 37
°C and in a humidified
culture incubator.
2.2. Reagents. Recombinant TGF-β1 was from R&D
(Minneapolis, MN). Anti phospho-Smad3 (pSmad3) anti-
bodies were purchased from Calbiochem (Darmstadt,
Germany). The anti-Smad2/3 (sc-8332) polyclonal antibody
was purchased by Santa Cruz Biotechnology Inc., CA.
α-Tubulin, appropriate secondary antibodies coupled to
horseradish peroxidase, FITC or TRIC, Smad3 inhibitor
SiS3, bovine plasminogen, and estramustine phosphate
(EP) were purchased from Sigma-Aldrich (St. Louis, MO).
2.3. ProliferationAssay.Todetermine theRAW264.7 cell pro-
liferation rate, by theMMT assay, we followed themethods of
Krstić et al. [26]. The following day, cells were treated by the
indicated EP concentrations for additional 24 or 72 hours. At
the end of this period, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MMT, Sigma-Aldrich) was
added to each well at 0.5mg/ml, and cells were incubated
for two additional hours. The culture medium was then
discarded, and the cell-precipitated formazan crystals were
dissolved in isopropanol: DMSO (3 : 2). The absorbance was
read at 630 nm.
2.4. Immunofluorescence Assay. Immunofluorescence analy-
sis was used to detect alpha-tubulin and pSmad3 in RAW
264.7 cells. Briefly, 105 cells were seeded per rounded cover-
slip in 24 well plates and allowed to grow until 50% of conflu-
ence. After, the indicated treatments cells were fixed with 4%
paraformaldehyde in PBS and permeabilized with 0.2%
Triton X-100 for 5 minutes. Cell monolayers were incubated
with specific primary antibodies, followed by incubation
with corresponding fluorescently labelled secondary antibod-
ies and 1μg/ml of 4′,6-diamidine-2′-phenylindole dihy-
drochloride (DAPI), Sigma-Aldrich (St. Louis, MO). After
mounting with DABCO-Mowiol, the samples were examined
and photographed using an epi-fluorescence microscope.
pSmad3 positive cells were quantified by counting the
number of positive cells in at least 5 different fields for each
experimental conditions.
2.5. Cell Migration Assays. To analyse cell migration, by
in vitro wound healing and Boyden chamber-based cell
migration assays, we followed the methods of Krstić et al.
[26]. Briefly, 5× 104 cells/well were seeded in 24 well plates
and allowed to grow until confluence. A scratch wound in
the monolayer was made by a 200μl pipette tip. Cells were
washed three times with PBS and allowed to migrate for addi-
tional 24 hours with the indicated treatments. Then, cells
were fixed with ice-cold methanol and stained for 30 minutes
with 0.1% crystal violet. Cell migration into the scratch area
was photographed using an inverted light microscope and
quantified by TScratch software (Computational Science
and Engineering Laboratory, Swiss Federal Institute of
Technology, ETH Zurich, Switzerland).
The migration capacity of RAW 264.7 cells was also
evaluated in a Boyden chamber-based cell migration assay
(Costar, Cambridge, MA) with 8.0μm pore polycarbonate
filters (Collaborative Research, Bedford, MA). Briefly, RAW
264.7 were labelled with carboxyfluorescein succinimidyl
ester (CFSE, Sigma-Aldrich), according to manufacturer’s
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instructions, and seeded in the upper chamber (105 cells per
transwell) in 150μl of growth medium. Growth medium
(0.5ml), with or without 5 ng/ml of TGF-β, as a chemoattrac-
tant factor, and EP were added in the lower chamber. After
18 h, cells from the upper compartment were cleaned with a
cotton swab to remove the nonmigrating cells. Cells attached
to the bottom of transwells were fixed by immersing the trans-
wells into 3.7% formaldehyde in PBS. After washing, trans-
wells were turned upside down, mounted with a coverslip,
and cells were observed using an epi-fluorescencemicroscope.
Green labelled cells from each sample were counted using
ImageJ software in eight random fields per transwell insert.
2.6. Urokinase-Type Plasminogen Activator Activity Assays.
uPA activity was determined by the radial caseinolysis assay
in the conditioned, serum-depleted media from indicated
RAW 264.7 cell treatments. Protein-normalized conditioned
medium aliquots (50μl) were added to the wells made in the
1% agarose gel containing 0.5% casein, 2μg/ml plasminogen,
and 10mM CaCl2. Diameters of clear areas were measured
after incubation at 37°C for 24h. uPA activity was estimated
as fold increase compared with conditioned medium from
untreated cells. The uPA degradation areas were quantified
by densitometry, using NIH-ImageJ software [16].
Cell culture supernatants were analysed for the presence
of secreted uPA also by the zymography assay. Briefly,
5× 104 cells/well were seeded in 24 well plates, cultured
overnight, and washed three times with PBS; then 0.5ml of
serum-free culture medium was added for additional 24 h
cultivation under indicated treatments. Aliquots of protein-
normalized conditioned medium were subjected to 10%
SDS-PAGE under nonreducing conditions. After being
washed with 2.5% Triton X-100, the gels were placed on 1%
agarose gels containing 0.5% casein and 2μg/ml plasminogen
and incubated at 37°C for 24 h. uPA-dependent proteolysis
was detected as a clear band in the agarose gel. The uPA
bands were quantified by densitometry, using NIH-ImageJ
software [27].
2.7. Western Blot Assay. To determine proteins by the
western blot assay, we followed the methods of Krstić et al.
[26]. Cells, cultivated in six well plates at density of
1.5× 106 cells/well, were lysed for 30min at 4°C in 200μl of
RIPA lysis buffer (1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, 150mM NaCl, 50mM Tris, pH7.5, with 1mM
Na3VO4 and protease inhibitors). Equal amounts of proteins
of each extract were separated by SDS-PAGE and transferred
to PDFV membranes (AppliChem, Darmstadt, Germany).
The membranes were blocked in 4% nonfat milk in PBS
buffer containing 0.5% Tween 20. The membranes were then
incubated with primary, and subsequently with horseradish
peroxidase-conjugated secondary antibodies. Specific protein
bands were visualized using the ECL reagent from Thermo
Scientific (Rockford, USA). The western blot bands were
quantified by densitometry, using NIH-ImageJ software.
2.8. Transfection and Luciferase Assays. The uPA promoter
transcriptional activity was determined by using a p-4.8
murine uPA–Luc luciferase reporter plasmid (provided by
Dr. Munoz-Canoves (CRG, Spain)) as described [27]. The
reporter assay with TGF-β/Smad3 responsive promoter
construct was performed using p (CAGA)12-Luc construct
as described [28]. Firefly luciferase activity, determined fol-
lowing manufacture’s recommendations (Promega, Adison,
WI, USA), was normalized for β-galactosidase activity
(Tropix, Bedford, MA, USA).
2.9. Statistical Analysis. Data are given as means (±SEM)
from at least three independent experiments. Student’s t-test
was performed to evaluate the probability of significant dif-
ferences among the samples with p < 0 05 (∗) and p < 0 005
(∗∗) considered significant.
3. Results
3.1. EP Cytotoxicity and RAW 264.7 Cells Cytoskeleton
Effects. Due to the fact that EP has been demonstrated to
interfere mitosis and trigger cell death [20, 21], we first
analysed the effects of EP on RAW 264.7 cell proliferation.
Cells were subjected to cell proliferation for 24 and 72 hours
(Figure 1(a)). Clear reduction of cell proliferation is observed
at 72 h of EP treatment, from 10% of inhibition at 2.5μM to
73% at 40μM. Meanwhile, at 24 h of EP treatment at 40μM,
only 18% cell reduction was obtained. Since next experiments
will be performed for a maximum of 24h, we decided to use
EP at 10μM to avoid proliferative interaction with the subse-
quent analyses. To confirm that EP 10μM affects tubulin
cytoskeleton, the immunofluorescence assay was performed
(Figure 1(b)). Epifluorescent imaging of α-tubulin revealed
a disruption of the interphase microtubules in treated cells
compared with control macrophages. Moreover, RAW
264.7 cells exhibited a spherical morphology in the presence
of EP (data not shown).
3.2. EP Inhibits TGF-β-Induced Cell Migration. TGF-β has
been demonstrated to induce macrophage cell migration
toward the site of inflammation [3]. Next, we examined
whether EP may interfere with macrophage motility deter-
mined by the wound healing assay. As observed in
Figure 2(a), 18 h of TGF-β treatment enhances the capacity
of RAW 264.7 cells to migrate into the wound in compar-
ison with the control cells, while the presence of EP 10μM
significantly abolished TGF-β-induced cell motility. EP
also inhibited TGF-β chemoattractant function, since it
reduced RAW 264.7 cell capacity to migrate through the
8μm pores to the bottom side of the membrane in a
Boyden chamber-based cell migration assay (Figure 2(b)).
The EP migration inhibition was related to changes in
the RAW 264.7 cell tubulin cytoskeleton. As shown in
Figure 2(c), EP modified the MT pattern compared with
TGF-β-treated cells. The effect of EP on TGF-β-induced
RAW 264.7 cells motility seems to be related to the changes
in MT cytoskeleton and not to modifying cell proliferation.
Neither TGF-β nor EP has shown to modify cell prolifera-
tion at the indicated experimental conditions (Figure 2(d)),
nor have they had significant effects on the cell cycle
(Supplementary Figure (available here)).
3Analytical Cellular Pathology
3.3. EP Inhibits TGF-β-Induced uPA Expression. Previous
reports indicate that TGF-β is a potent inductor of uPA
expression in macrophages and uPA contributes to macro-
phage cell migration [14, 15, 25]. We analysed whether EP
inhibits the capacity of TGF-β to induce uPA in RAW
264.7 cells. The radial caseinolysis assay revealed that EP
inhibited TGF-β-induced uPA secretion of RAW 264.7 cells,
which is evident between 2.5 to 10μMof EP (Figure 3(a)). EP
inhibition of TGF-β-induced uPA secretion seems to affect
uPA expression at the transcriptional level, since the drug
strongly inhibited the capacity of TGF-β to enhance the
transactivation of the uPA promoter. Thus, these data sug-
gested that EP, in part, reduced TGF-β enhancement of
RAW 264.7 cell migration by blocking uPA expression incre-
mented by the growth factor.
3.4. EP Inhibits Smad3 Activation by TGF-β Paralleled with
Smad3-Dependant Migration and uPA Expression.We previ-
ously demonstrated that TGF-β induces uPA expression by
Smad3 signaling [25], and Smads have been reported to be
associated with MT cytoskeleton [24]. Subsequently, we
examined whether EP effect on the tubulin network may
modify Smad3 activation by TGF-β. As shown in
Figure 4(a), the western blot assay revealed that EP strongly
inhibits the capacity of TGF-β to induce Smad3 phosphory-
lation, which is accompanied with a decrease of the nuclear
phospho-Smad3 presence after TGF-β and EP cotreatment
(Figure 4(b)). This diminution in Smad3 phosphorylation
and nuclear translocation was paralleled with EP inhibition
of TGF-β-induced transactivation of the Smad3 reporter
(Figure 4(c)), which confirms that EP, by interfering on the
MT cytoskeleton network, inhibits the capacity of TGF-β to
activate Smad3 signaling. The importance of Smad3 on
TGF-β-induced RAW cell migration was demonstrated by
using the chemical Smad3 inhibitor SiS3. Figure 4(d) shows
that SiS3 at 5μM reduced the capacity of TGF-β to increment
cell migration analysed by the wound healing assay. More-
over, SiS3 is also able to reduce TGF-β-induced uPA produc-
tion as revealed by zymography analysis (Figure 4(e)). These
data suggest that EP, via its interference on MT cytoskeleton,
inhibits TGF-β-induced RAW 264.7 cells motility and uPA
expression by reducing Smad3 activation.
4. Discussion
TGF-β, in the immune system, has been demonstrated to
profoundly modulate monocyte/macrophage functions [3].
TGF-β promotes recruitment of monocytes, and it may pro-
mote monocyte to macrophage differentiation [29]. For
instance, TGF-β promotes macrophage polarization toward
an M2-versus-M1 phenotype, which further promotes
TGF-β production and deepens TGF-β-induced immuno-
suppression [4, 30, 31]. Moreover, in tumor microenviron-
ment, TGF-β induces macrophage differentiation toward a
TAM-like (M2-like) phenotype [23], which further supports
tumor growth. Actually, TAMs seem to be crucial and the
most abundant immune cell components in tumor microen-
vironment [32]. Furthermore, in cancer, the TAM level is
strongly associated with poor prognosis and survival, which
made these cells attractive targets for chemotherapeutic
interventions [33]. In this study, by using RAW 264.7 murine
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Figure 1: EP on RAW 264.7 cell proliferation and tubulin cytoskeleton. (a) RAW 264.7 cells were treated with increasing concentrations of
EP for one or three days, and cell proliferation was determined in a triplicate experiment by the MTT assay. At day one, EP showed reduced
capacity of inhibiting cell proliferation compared to three-day treatment. RU: relative units. (b) One-day EP treatment, at 10μM, modified
tubulin cytoskeleton determined by immune fluorescence (red). Nuclei were counterstained with DAPI (blue). Representative
microphotographs from three independent determinations are shown.
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widely antineoplastic agent that interferes with MT dynam-
ics, on TGF-β-induced cell migration and uPA expression.
TGF-β is a pleotropic factor that possesses a dual role in
tumorigenesis, since it acts as tumor suppressor at early steps
of tumor progression, while it is a prometastatic cytokine in
aggressive cancer stages [34]. Moreover, excessive TGF-β
levels recruit monocytes within tumor microenvironment
and may promote the alternative activation of M2 macro-
phages in detriment of M1 polarization, thereby promoting
tumor progression [8]. The recruitment of monocytes-
macrophages to tumor stroma requires intense acquisition
of motile cell phenotype. Cell migration implies the contribu-
tion of regulatory pathways spatially and temporary engaged
with cytoskeleton plasticity and reorganization [16, 35]. Actu-
ally, tubulin cytoskeleton is a key for the establishment of cell
polarity, cell extensions, and cell migration. Furthermore, the
microtubule network finely coordinates with actin filaments
for proper cell migration [36, 37]. To determine the role of
microtubule in macrophage cell migration, we used EP as a
microtubule dynamic interfering agent. Namely, in vitro
analysis indicated that estramustine and EP bind to tubulin
dimers and to microtubule-associated proteins, inhibiting
microtubule assembly and suppressing the dynamic insta-
bility of individual MAP-free microtubules [20]. Here, we
used noncytotoxic EP concentration (10μM) for 24hours
of treatment, which effectively modified the RAW 264.7 cell
microtubule network (Figure 1), to determine its effect on
TGF-β cell response. It has been demonstrated that TGF-β
induces monocyte/macrophage cell migration to the site of
injury [37, 38]. Our results also indicated in vitro TGF-β
increased cell migration in wound healing and Boyden
chamber-based cell migration assays (Figure 2), whose effects
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Figure 2: EP inhibits TGF-β-induced RAW 264.7 cell migration. (a) Cells were cultured until confluence, and a scratch at the centre of
monolayer was made. Then, cells were treated as indicated for 24 hours, fixed and stained. 10μM EP significantly inhibits the closure of the
wound induced by TGF-β 5 ng/ml. (b) RAW 264.7 cells were subjected to chemoattractant response to TGF-β 5 ng/ml by using the Boyden
chamber-based assay. CFSE stained cells were allowed to migrate across the 8μm pore membrane for 18 hours. Microphotographs show
fixed cells in the bottom of the membrane (green). EP 10 μM significantly reduced TGF-β chemoattractant potency. (c) EP modified tubulin
cytoskeleton in the presence of TGF-β. Cells were treated with TGF-β 5 ng/ml in the presence or absence of EP 10μM for 24 h. Then, cells
were subjected to immunofluorescence analysis for tubulin cytoskeleton (red) and nuclei (blue). (d) Neither TGF-β nor EP modified RAW
264.7 cell proliferation, determined by the MTT assay. RU: relative units. Representative results from three independent experiments are
shown. Significant difference between treatments by t-test: ∗p < 0 05.
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were strongly inhibited by EP. This inhibition implicated the
EP-dependent changes of the MT network but without effect
on cell proliferation, since neither TGF-β alone nor in the
mix with EP modified cell growth in our experimental condi-
tions (Figure 2(d) and Supplementary Figure). These results
suggested that EP treatment interfered with the stimulation
of cell migration and the chemoattractant activity of TGF-β
on murine macrophages.
The cell capacity to breakdown the ECM is also one of the
main mechanisms implicated in cell migration [39]. In that
sense, macrophages highly produce several ECM-degrading
proteases, such as matrix metalloproteases, cathepsins, and
uPA, which are implicated in both macrophage migration
and in enhancement of migration of cancer cells [40].
Specifically, uPA has been demonstrated to contribute to
macrophage migration and invasion. uPA can stimulate
macrophage migration, and the silence of uPA or its receptor
uPAR impairs in vivo macrophage tumor infiltration as well
as in vitro Matrigel invasion [11, 14]. Moreover, uPA is a key
mediator of macrophage 3D invasion and ECM remodelling
[15]. TGF-β is a potent inductor of the uPA gene transcrip-
tion; it increases uPA-mRNA stability and activates macro-
phage uPA expression [41, 42]. Our results indicate that EP
strongly inhibited TGF-β capacity to stimulate uPA expres-
sion in RAW 264.7 cells (Figure 3). This effect seems to
involve the uPA transcriptional gene inhibition mechanism,
since EP decreased TGF-β-induced uPA promoter transacti-
vation, which may indicate that EP by modulating MT
network dynamics may interfere with TGF-β intracellular
signaling propagation to the nucleus. Also, these data allowed
us in part to exclude the involvement of EP on uPA transport
and exocytosis, since MT are highly implicated in secretory
pathways as well [43].
We previously investigated the intracellular signal
transduction implicated in the capacity of TGF-β to
induce uPA expression in RAW 264.7 cells. We demon-
strated that Smad3, a member of the canonical TGF-β sig-
naling, contributes to the increased production of uPA
[25]. Intriguingly, TGF-β–Smad signaling has been shown
to be regulated by tubulin cytoskeleton. Dong et al. [24]
demonstrated that the total disruption of the MT network
increased cell TGF-β responses, thus indicating MT as a
negative regulator of TGF-β–Smads signaling. We found
out that EP inhibited TGF-β-induced Smad3 phosphoryla-
tion, it reduced phospho-Smad3 nuclear localization, and
it decreased Smad3 transcriptional activity. In addition
and as we expected, the inhibition of Smad3 signaling by
using the chemical inhibitor SiS3 [44] greatly reduced
TGF-β-induced macrophage migration and uPA produc-
tion (Figure 4 and [25]). MT undergoes stochastic changes
between polymerization and depolymerization, namely,
dynamic instability [45], and any interference with this
dynamic may affect the signal propagation from the extracel-
lular to the nucleus. Estramustine, at the range of concentra-
tion used in this study, has been demonstrated to suppress
the dynamic instability by incrementing tubulin acetylation
that is implicated in MT stabilization [21]. So, we can specu-
late that EP, by stabilizing MT, may reduce the release of
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Figure 3: EP inhibits TGF-β-induced uPA production. (a) RAW 264.7 cells were cultivated with serum-free media for 24 h in the presence
of TGF-β at 5 ng/ml and indicated EP concentrations. Then conditioned media were subjected to the radial caseinolysis assay. Degradation
areas represent uPA activity. Increased EP concentration strongly inhibits the TGF-β capacity to induce uPA production. (b) EP inhibits
TGF-β-induced uPA promoter transactivation. RAW 264.7 cells were transfected with a p-4.8 murine uPA–Luc luciferase reporter
plasmid. Then, cells were subjected to TGF-β 5 ng/ml treatment in the presence or absence of EP 10 μM. RLU: relative luciferase units.
Representative results from three independent experiments are shown. Significant difference between treatments by t-test: ∗p < 0 05
and ∗∗p < 0 005.
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Smad3 from cytoskeleton to interact with the TGF-β type I
receptor (T β RI), therefore inhibiting Smad3 phosphoryla-
tion. Furthermore, it has been demonstrated that TGF-β
induces T β RI interaction with microtubules in a Smad7/
adenomatous polyposis coli-dependent fashion to regulate
migratory responses [46], which also can be interfered by
EP effect on MT. Further experiments are necessary to
challenge whether EP interferes with TβRI and Smad3
interaction in RAW 264.7 cells.
EP estrogenic effects may also be involved on the regula-
tion of TGF-β signaling, either by the estradiol-17β part of
EP or by estradiol releasing as results of EP hydrolysis [22].
In this sense, estradiol by inhibiting Smad and RHO signal-
ing reduces the capacity of TGF-β to induce fibroblast
activation [47]. In addition, estradiol inhibits TGF-β induc-
tion of extracellular matrix in human and rat mesangial cells
[48]. Further experiments are necessary to determine
whether estrogenic EP properties, beyond its tubulin cyto-
skeleton modulation capacity, may affect TGF-β signal
transduction in macrophages.
Macrophages play important roles in the tumor progres-
sion [49], and it is critical to elucidate the EP in vivo effects as
well as in primary macrophages such as mouse peritoneal
macrophages or bone marrow macrophages. In this study,
we used immortalized macrophage cell line RAW 264.7,
which limits the scope of our results. Further extensive stud-
ies in vivo, in primary healthy and tumor-associated macro-
phages, are necessary to validate and fully understand EP
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Figure 4: EP inhibits TGF-β-induced Smad3 activation. (a) TGF-β 5 ng/ml was used to one-hour stimulation of RAW 264.7 cells in the
presence or absence of EP 10μM. Then, samples were subjected to the WB assay to determine Smad3 phosphorylation levels. EP reduced
the capacity of TGF-β to increase phospho-Smad3 levels. (b) Nuclear phospho-Smad3 localization. Cells were treated for one hour with
TGF-β 5 ng/ml in cotreatment with EP 10μM. Then cells were subjected to the immunofluorescence assay for Smad3 (green) and nuclei
DAPI stains (blue). EP reduced the TGF-β-induced pSmad3 nuclear levels as is indicated by the number of pSmad3 positive cells. (c) EP
inhibits Smad3 responsive p (CAGA)12-Luc construct transactivation. Transfected cells were treated with TGF-β 5 ng/ml with or without
EP 10 μM for 24 h. Then, luciferase activity was determined. RLU: relative luciferase units. (d) Direct Smad3 inhibition by using SiS3
reduces TGF-β-induced cell migration, determined by the wound healing assay. (e) Smad3 inhibition decreases TGF-β-induced uPA
secreted activity, determined by the zymography assay. Representative results from three independent experiments are shown. Significant
difference between treatments by t-test: ∗p < 0 05 and ∗∗p < 0 005.
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modulation of TGF-β signaling and its effects in macrophage
biology. Therefore, due to the importance of TAMs in
tumor progression, it will be worthy to further examine if
EP may reeducate macrophages from protumorigenic M2
phenotype to M1 activation, which can suppress tumor
growth and angiogenesis [50]. The MT stabilization by
using anti-MT drugs may promote macrophage polarization
toward M1 phenotype [51], which suggests MT dynamics
modulation as an emerging attractive strategy for thera-
peutic intervention of protumorigenic macrophage infiltra-
tion within tumor microenvironment.
5. Conclusions
The obtained results indicate that EP reduced TGF-β-induced
uPA expression and cell migration, in part, by inhibiting
Smad3 activation inmurinemacrophage RAW264.7 cell line.
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Supplementary Materials
RAW cells were treated for 24 hours with TGF-β 5ng/ml
with or without EP 10μM. Then, cells were subjected to flow
cytometer cell cycle analysis. Briefly, treated cells were 3x PBS
washed and fixed with 70% cold ethanol. Then, cells were
treated with RNAse A (10μM/ml)/PBS for 30 minutes and
stained with propidium iodide (5μg/ml). The figure shows
that cell treatments did not modify the cell frequency (%)
in the different cell cycle phases. (Supplementary Materials)
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